http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3691681-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a10dc651e733b8d5a1ec5684b812362 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24171 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2018-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed4e23ba0327aec430ee706430d9cab7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c033a17b82a4bb399f502cb44e935ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e4967a97e35e254cddce19d8c7a78d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c2dfd1ff9fd5fe0649b89da19dc28a7 |
| publicationDate | 2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3691681-A1 |
| titleOfInvention | Compositions for booster vaccination against dengu |
| abstract | The present invention relates to a booster vaccination method and a vaccine composition for use in said method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of the serotypes 1 to 4 of the present invention. dengue virus and was not immunized against dengue fever prior to said primary vaccination.nThe composition according to the invention comprises a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, and said booster vaccination gives rise to an increase of 2 times the titre of neutralizing antibodies against each of serotypes 1 to 4. The invention also relates to a method of induction in a human subject of a neutralizing antibody response comprising the administration of a vaccine composition, or a composition vaccine for use in said method, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4, or a nucleic acid construct capable of expressing in said subject a dengue antigen of each of the serotypes 1 at 4; is administered as a primary vaccination, followed by a booster vaccination, and the human subject is initially not immunized against dengue fever. |
| priorityDate | 2017-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.